Low-Dose Naltrexone and Pregabalin Interaction

Why These Two Drugs Are Commonly Co-Prescribed

LDN and pregabalin both appear in fibromyalgia and chronic pain management, though they work through entirely different receptor systems. The overlap in patient populations makes the combination question one that clinicians encounter regularly.

Fibromyalgia and Central Sensitization

Fibromyalgia affects an estimated 2% to 4% of the U.S. Population 1. Pregabalin became the first FDA-approved drug for fibromyalgia in 2007, based on trials showing a 30% pain reduction in roughly half of treated patients at 300 to 450 mg/day 2. LDN, compounded at 1 to 4.5 mg, lacks FDA approval for any indication at this dose range but has accumulated pilot trial evidence in fibromyalgia. Younger et al. (2013, N=31) demonstrated that LDN 4.5 mg reduced fibromyalgia pain by 28.8% compared to placebo (P=0.016) 3.

Why Clinicians Consider the Combination

Pregabalin targets alpha-2-delta calcium channel subunits to reduce excitatory neurotransmitter release. LDN is proposed to act through toll-like receptor 4 (TLR4) antagonism on glial cells, reducing neuroinflammation 4. Because these mechanisms are independent, some pain specialists prescribe them together when monotherapy provides incomplete relief. The FDA label for naltrexone (Revia) does not list pregabalin as a contraindicated co-medication 5, and the FDA label for pregabalin (Lyrica) does not list naltrexone 6.

Pharmacokinetic Assessment: No Metabolic Conflict

The two drugs are processed by entirely separate systems. This is the central reason there is no pharmacokinetic interaction.

Naltrexone Metabolism

Naltrexone undergoes extensive first-pass hepatic metabolism. The primary pathway involves dihydrodiol dehydrogenase, which converts naltrexone to its major active metabolite 6-beta-naltrexol 5. A minor role is played by CYP3A4. Naltrexone does not inhibit or induce any major CYP enzymes at standard doses (50 mg). At the 1 to 4.5 mg range used for LDN, systemic exposure is a fraction of standard dosing. Plasma concentrations peak around 1 hour after oral administration, with an elimination half-life of approximately 4 hours for the parent compound and 12 hours for 6-beta-naltrexol.

Pregabalin Metabolism

Pregabalin bypasses hepatic metabolism almost entirely. According to the Lyrica prescribing information, less than 2% of the dose undergoes biotransformation 6. The drug is eliminated renally as unchanged compound, with a half-life of 6.3 hours. It is not bound to plasma proteins. It does not inhibit or induce CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4. It is not a substrate of P-glycoprotein.

The Interaction That Doesn't Happen

Because naltrexone relies on dihydrodiol dehydrogenase and minor CYP3A4 activity, while pregabalin skips the liver altogether, there is no enzyme competition, no transporter conflict, and no displacement from protein binding (pregabalin is unbound; naltrexone is approximately 21% protein-bound). Neither drug alters the absorption, distribution, or clearance of the other 5 6.

Pharmacodynamic Considerations: Separate Targets, Some Shared Effects

While the metabolic profiles are independent, both drugs act within the central nervous system. The pharmacodynamic profile deserves closer attention than the pharmacokinetic one.

Mechanism Comparison

LDN at 1 to 4.5 mg is hypothesized to produce a brief, transient opioid receptor blockade that upregulates endogenous opioid production (endorphins, met-enkephalin) through a rebound mechanism 4. Separately, LDN may antagonize TLR4 on microglia, reducing release of pro-inflammatory cytokines including interleukin-6 and tumor necrosis factor-alpha. A 2014 review by Younger et al. Characterized this dual mechanism as the basis for LDN's proposed anti-inflammatory and analgesic effects 4.

Pregabalin binds the alpha-2-delta-1 subunit of voltage-gated calcium channels in dorsal root ganglia and spinal cord dorsal horn neurons 7. This binding reduces calcium influx and downstream release of glutamate, norepinephrine, and substance P. The net effect is reduced excitatory signaling in pain pathways.

Potential Additive CNS Effects

Both drugs can cause dizziness. Pregabalin trials report dizziness rates of 29% to 38% at therapeutic doses 6. LDN users report dizziness at lower rates (under 10%), though formal incidence data from controlled trials is limited. Somnolence affects approximately 15% to 22% of pregabalin users. LDN can cause vivid dreams and sleep disturbance in the first weeks of use, reported in 37% of participants in one pilot study 3.

When prescribing both, a staggered start protocol reduces the difficulty of attributing side effects. Begin pregabalin first (the agent with the larger side-effect footprint), titrate to a stable dose over 1 to 2 weeks, then introduce LDN at 1.5 mg nightly and increase by 0.5 to 1.5 mg every 1 to 2 weeks.

Opioid Interaction Consideration

One area where the pharmacodynamic profile matters clinically: if a patient takes any opioid alongside pregabalin, adding LDN is contraindicated. Naltrexone, even at low doses, can precipitate withdrawal in opioid-dependent individuals 5. This applies to any opioid, including tramadol, codeine, and opioid-containing cough suppressants. The Revia label recommends patients be opioid-free for a minimum of 7 to 10 days before initiating naltrexone.

DDI Database and Guideline Review

No major drug-drug interaction databases classify the LDN-pregabalin combination as contraindicated, major, or even moderate severity.

What the Databases Say

Lexicomp, Micromedex, and Clinical Pharmacology do not flag naltrexone-pregabalin as an interaction pair. The reason is straightforward: the absence of shared metabolic pathways and the absence of directly opposing receptor activity means neither drug changes the other's efficacy or safety profile in a clinically meaningful way.

Why No Formal Interaction Studies Exist

No published pharmacokinetic interaction study has been conducted specifically for naltrexone plus pregabalin. The FDA does not require interaction studies between drugs that use entirely unrelated metabolic and elimination pathways. A 2021 review of LDN drug interactions noted that naltrexone at low doses has a "minimal interaction profile" owing to its low systemic exposure and non-CYP-dependent primary metabolism 8.

Monitoring Recommendations

Even without a pharmacokinetic interaction, monitoring is appropriate when combining any two CNS-active agents.

Baseline and Ongoing Labs

Naltrexone carries a boxed warning for hepatotoxicity at doses of 300 mg/day or higher (five to six times the standard 50 mg dose) 5. At LDN doses of 1 to 4.5 mg, hepatotoxicity risk is negligible. The FDA label for Revia recommends baseline liver function tests (ALT, AST) and periodic monitoring. For LDN, many clinicians obtain baseline LFTs and recheck at 3 months, then annually.

Pregabalin requires renal function assessment (eGFR or creatinine clearance) before initiation, as dose reduction is required when CrCl falls below 60 mL/min 6. The dose should be reduced proportionally: 150 mg/day maximum for CrCl 15 to 29 mL/min.

Clinical Symptoms to Track

Three symptom domains warrant monitoring in the first 4 to 6 weeks of combination use:

1. Dizziness and somnolence. Ask the patient to rate these on a 0 to 10 scale at each visit. If dizziness exceeds 4/10 or impairs daily function, reduce pregabalin first (the more likely contributor).

2. Sleep quality. LDN-associated vivid dreams typically resolve within 2 to 4 weeks 3. If they persist, a morning dosing switch for LDN may help, though evening dosing is more common in practice.

3. Peripheral edema. Pregabalin causes dose-dependent peripheral edema in 2% to 16% of patients 6. LDN does not contribute to this, but the symptom should not be attributed to LDN if it appears after combination initiation.

Dose Adjustment Guidance

No dose adjustment of either drug is needed based on the pharmacokinetic profile of the other.

LDN Dosing

Standard LDN titration starts at 1 to 1.5 mg orally at bedtime, increasing to 4.5 mg over 2 to 8 weeks. This schedule does not change when pregabalin is on board. The Younger et al. Fibromyalgia trials used a fixed 4.5 mg dose 3.

Pregabalin Dosing

The approved pregabalin dose range for fibromyalgia is 300 to 450 mg/day divided into two or three doses 6. For neuropathic pain, the range extends to 600 mg/day. These doses are not altered by co-administration with LDN. The only factor that changes pregabalin dosing is renal function.

When to Reconsider the Combination

If a patient reports no benefit from LDN after 8 to 12 weeks at 4.5 mg, discontinuation is reasonable. LDN has no withdrawal syndrome and can be stopped without tapering 8. Pregabalin, by contrast, should be tapered over at least one week to avoid withdrawal symptoms including insomnia, nausea, headache, and diarrhea 6.

Patient Counseling Points

Clear communication reduces unnecessary alarm and improves adherence.

What to Tell Patients

Start with the most common question: "These two medications do not interfere with each other's absorption or breakdown in the body." Then address the practical points.

Vivid dreams from LDN are expected in the first 2 to 4 weeks and do not indicate a drug interaction. Dizziness from pregabalin may feel slightly worse in the first few days after adding LDN, but this is not a sign of danger. Patients should avoid driving or operating heavy machinery until they know how the combination affects them.

The Opioid Rule

Any patient on this combination must be told directly: do not take any opioid medication, including over-the-counter cough syrups containing codeine or dextromethorphan at high doses, without contacting your prescriber first. Even at 1 to 4.5 mg, naltrexone can block opioid receptors sufficiently to interfere with opioid analgesia 5. Patients scheduled for surgery should discontinue LDN at least 72 hours prior and inform the anesthesiologist.

Alcohol

Pregabalin's prescribing information warns against concurrent alcohol use due to additive CNS depression 6. Naltrexone at full dose (50 mg) is used to reduce alcohol craving, but at LDN doses, the anti-craving effect is not established. Patients should still limit alcohol while on pregabalin regardless of LDN status.

Special Populations

Renal Impairment

Pregabalin dose must be adjusted for renal impairment; LDN does not. In patients with CrCl of 30 to 59 mL/min, the maximum pregabalin dose drops to 300 mg/day 6. LDN dosing remains 1 to 4.5 mg regardless of renal function, since naltrexone and 6-beta-naltrexol are cleared hepatically.

Hepatic Impairment

This reverses: naltrexone is hepatically metabolized, so patients with hepatic impairment require LFT monitoring before and during LDN use 5. Pregabalin does not require hepatic dose adjustment.

Older Adults

Adults over 65 may have reduced renal clearance affecting pregabalin exposure. The Lyrica label recommends dosing based on creatinine clearance rather than age alone 6. Fall risk increases with both dizziness-causing agents on board. A lower starting pregabalin dose (75 mg/day) with slower titration is advisable. LDN starting doses of 1 mg are appropriate for older adults.